williamrreddin

Respiratory Syncytial Virus, commonly known as Human Respiratory Syncytial Virus, is a contagious virus that affects the respiratory system and causes lung illness in the body. Children are most commonly infected by the virus. The Centers for Disease Control and Prevention (CDC) estimate that one to two out of every 100 children under the age of six months who have Respiratory Syncytial Virus (RSV) infection may require hospitalization. According to information from the National Institutes of Health (NIH), RSV affects more than 64 million individuals annually on a global scale. The Global  Respiratory Syncytial Virus Market   revenue was around US$ 1823.3 million in 2022 and is estimated to reach US$ 4202.6 million by 2027, growing at a compound annual growth rate (CAGR) of 14.9% over the projection period from 2022 to 2027. The market has experienced considerable growth as a result of the respiratory syncytial virus's rising prevalence, and the discovery of tailored medicines...

Respiratory Syncytial Virus or Human Respiratory Syncytial Virus. It is an infectious virus that affects the respiratory system and worsens lung infections in humans. One of the main drivers of market expansion is the rising sickness rate. Over 57,000 children under the age of five in the United States require hospital care each year as a result of RSV, according to data released by the Cleveland Clinic. In addition, RSV causes roughly 177,000 adult hospital admissions annually.     The global Respiratory syncytial virus market is estimated to reach a valuation of US$ 4,202.6 million by 2027, registering a CAGR of 14.9% over the forecast period 2022-2027. The market growth considers the industry recovery from Covid-19 and the substantial shift in the growth trend. However, the respiratory syncytial virus market accounted for a revenue of US$ 1,823.3 Million in 2021. Download Sample of This Strategic Report:-   https://www.astuteanalytica.com/request-sample/respiratory-sy...